Tumour and dendrimers: a review on drug delivery aspects

被引:44
作者
Agarwal, Abhinav [1 ]
Asthana, Abhay [1 ]
Gupta, Umesh [1 ]
Jain, Narendra K. [1 ]
机构
[1] H S Gour Univ, Dept Pharmaceut Sci, Pharmaceut Res Labs, Sagar 470003, MP, India
关键词
D O I
10.1211/jpp.60.6.0001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tumour is a morbid state, characterized by spontaneous outgrowth of an abnormal mass of cells. The evolution of tumours is random, disorganized, a condition of numerous mutations. The properties are biased and incompletely comprehended. It is a malignant or benign condition that encompasses its own rules of morphogenesis, an immortal state that elucidates different physiology. It is a pathological crisis that still haunts the minds of scientists, physicians and patients, a complete cure of which is still a dream to be realized. The unpredictable microenvironment of cancerous cells in all of its existing forms i.e. leukaemic cells, solid tumours and sarcomas is well documented. This phenomenon expressed by cancerous sites in the body poses various obstacles towards drug efficacy. Thus, it has become necessary to address briefly the issues relating to tumour physiology, its vasculature and angiogenesis. The information could provide insight towards the development of tumour-targeted drug delivery. The salient features regarding these have been discussed.
引用
收藏
页码:671 / 688
页数:18
相关论文
共 161 条
[1]  
Abaan OD., 2002, TURK J MED SCI, V32, P283
[2]   Molecular mechanisms of lymphangiogenesis in health and disease [J].
Alitalo, K ;
Carmeliet, P .
CANCER CELL, 2002, 1 (03) :219-227
[3]   Dendrimeric micelles for controlled drug release and targeted delivery [J].
Ambade, Ashootosh V. ;
Savariar, Elamprakash N. ;
Thayumanavan, S. .
MOLECULAR PHARMACEUTICS, 2005, 2 (04) :264-272
[4]  
[Anonymous], ANTIBODY IMMUNOCONJ, DOI DOI 10.1007/S11060-004-8323-Y
[5]  
[Anonymous], VASCULAR TARGETED TH
[6]  
AREF M, 2001, P INT SOC MAG RES ME, V9, P2246
[7]  
ARSPE MLI, 2005, ANGIOGENESIS, P1
[8]   Dendrimers: a new class of nanoscopic containers and delivery devices [J].
Aulenta, F ;
Hayes, W ;
Rannard, S .
EUROPEAN POLYMER JOURNAL, 2003, 39 (09) :1741-1771
[9]  
Azzam Tony, 2004, Current Drug Delivery, V1, P165, DOI 10.2174/1567201043479902
[10]   Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature [J].
Backer, MV ;
Gaynutdinov, TI ;
Patel, V ;
Bandyopadhyaya, AK ;
Thirumamagal, BTS ;
Tjarks, W ;
Barth, RF ;
Claffey, K ;
Backer, JM .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) :1423-1429